Published May 12, 2023 | Version v1
Journal article Open

Uso de empagliflozina en pacientes con enfermedad renal crónica

Authors/Creators

  • 1. Medicina Familiar y Comunitaria. Hospital de Torrejón

Description

Se diseñó el estudio EMPA-KIDNEY para evaluar los efectos del tratamiento con empagliflozina en pacientes con enfermedad renal crónica. Demostró que su uso conllevó un menor riesgo de progresión de la enfermedad o de muerte por causas cardiovasculares, en comparación con el tratamiento con placebo.

 

 

The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in patients with chronic kidney disease. This empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.

Files

Journal 60 - 11.pdf

Files (2.0 MB)

Name Size
md5:3ddea3b11f6e5975b757f2b402afa61f
2.0 MB Preview Download

Additional details

References

  • Vol 380 N9854; págs. 1662-1673. 2012. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. The Lancet. doi: https://doi.org/10.1016/s0140-6736(12)61350-6
  • Vol 389 N10075; págs. 1238-1252. 2017. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The Lancet 2017. doi: https://doi.org/10.1016/s0140-6736(16)32064-5
  • Vol 345 N12; págs 861-869. 2001. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejmoa011161
  • Vol 345 N12; págs 851-860.2001. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejmoa011303
  • Vol 329 N20; págs 1456-1462. 1993. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejm199311113292004
  • Vol 380 N24; págs 2295-2306. 2019. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejmoa1811744
  • Vol 383 N15; págs 1436-1446. 2020. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejmoa2024816
  • Vol 383 N23; págs 2219-2229. 2020. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. The New England Journal of Medicine. Doi: https://doi.org/10.1056/nejmoa2025845